GET DAILY SIGNALSMediWound Ltd. (MDWD): Can Shares Reach the $30 Analyst Target?
Key Takeaways
- The $30 central target is the arithmetic mean of five verified analyst price targets, rounded from a calculated average of $29.60.
- Recent share prices around $12.97 leave an implied upside of about 131% to reach $30 — a very large move by any standard.
- The analyst target range is wide, spanning approximately $25 to $36, reflecting sharp disagreement over the value of the EscharEx pipeline.
- The strongest support comes from the late-stage EscharEx Phase III VALUE trial and growing NexoBrid commercial traction through partner Vericel (VCEL).
- The biggest risks are declining revenue, heavy reliance on U.S. government development services, cash burn, and recent dilution.
- For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
- To see how AI evaluates changing market conditions across thousands of tickers, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Five current, attributable price targets were reviewed to build the central figure. H.C. Wainwright holds a Buy rating with a $36 target, while Maxim Group and Oppenheimer each carry $30 targets, Alliance Global Partners has a $27 target, and TD Cowen has a $25 target. Averaging these five values produces $29.60, which rounds to the $30 central target used here. The low-to-high range of $25 to $36 underscores how much analyst opinion diverges.
The ratings skew heavily bullish — a "Strong Buy" orientation with no Holds or Sells among recently reporting firms — but the wide spread reflects genuine uncertainty. Bullish analysts emphasize the potential of EscharEx, an investigational therapy for debridement of chronic wounds, whose U.S. peak-sales opportunity management has estimated at roughly $1.05 billion after adding pressure ulcers to the analysis. More cautious targets acknowledge that the company's current revenue is shrinking and that the pivotal clinical readout remains in the future. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares recently trading near $12.97 and a 52-week range of roughly $11.80 to $19.70, the stock sits well below both its yearly high and the $30 target. Reaching $30 would require a gain of about 131%, which must be classified as a very large move rather than a modest one.
The company reported third-quarter 2026 revenue of $3.6 million, down from $5.4 million a year earlier, and a net loss of $6.0 million, or $0.47 per share. Revenue remains heavily weighted toward development services tied to U.S. government programs, while product sales are constrained by manufacturing capacity rather than demand. Any path toward $30 would likely require a successful EscharEx VALUE trial readout, a resumption of revenue growth, and continued NexoBrid adoption.
What Could Support a Move Toward the Target
Several verified factors underpin the bullish case. EscharEx's global Phase III VALUE trial in venous leg ulcers, targeting 216 patients, is expected to reach its interim sample-size assessment and complete enrollment by the first quarter of 2027, with top-line data to follow. Management has guided to substantial revenue growth in coming years — $24–26 million in 2026, $32–35 million in 2027, and $50–55 million in 2028 — contingent on U.S. government support and potential EscharEx contributions.
NexoBrid, the company's FDA-approved biologic for removal of eschar in thermal burns, is gaining commercial traction. Partner Vericel (VCEL) reported NexoBrid's strongest quarter since launch, with more than 80 burn centers ordering to date. A BARDA framework valued at up to $197 million and non-dilutive U.S. Department of Defense funding for a room-temperature formulation broaden the opportunity set.
What Could Prevent the Target From Being Reached
The risks are material. Revenue fell sharply in 2026 — $8.1 million in the first nine months versus $15.1 million a year earlier — because development-services revenue declined. Cash, equivalents, and deposits totaled $28.4 million at the end of September 2026 after $28.3 million of cash burn in nine months, and the company closed a $17.25 million public offering in November, adding dilution.
Clinical risk is the central variable: a disappointing or inconclusive VALUE trial readout, a required expansion of the sample size, or regulatory delays could reset expectations. NexoBrid supply is capacity-limited, and expanded-facility commercial supply is not expected until the second half of 2027. Competition in wound debridement, including Smith & Nephew's SANTYL franchise, also persists.
Technical Levels and Market Structure
The stock's 52-week low near $11.80 marks a key support level, while the yearly high near $19.70 represents a durable resistance zone. Between current prices and $30, there is little established trading history, meaning the $20 area and any psychological round numbers would be watched as potential resistance on a recovery. The long-term trend has been negative, with the shares down roughly 25% to 30% over the past year.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though this is an assumption and individual firms' horizons can differ. The most consequential upcoming items are the EscharEx VALUE trial interim assessment and enrollment completion expected by the first quarter of 2027, followed by top-line data, plus NexoBrid regulatory approvals for the expanded manufacturing facility and the resolution of U.S. government funding discussions. Quarterly revenue trends, cash position, and any further financing will also matter.
Using AI Daily Buy/Sell Signals in Practice
In my own workflow, I turn to AI Daily Buy/Sell Signals when following event-driven names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. It helps me put price action into broader context without having to review every chart manually, which is especially useful around clinical or earnings milestones.
Final Assessment
The $30 target is the rounded average of five current analyst price targets spanning roughly $25 to $36. From a recent price near $12.97, reaching it would require a gain of about 131% — a very large move that would depend heavily on the EscharEx VALUE trial delivering positive results and on NexoBrid's commercial ramp accelerating. Supporters point to a large chronic-wound market opportunity and growing government backing, while skeptics emphasize shrinking revenue, cash burn, and dilution. The wide analyst range shows genuine disagreement, and no outcome is guaranteed; the EscharEx readout and near-term revenue trajectory are the key data points to watch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDWD in downward trend: price may drop because broke its higher Bollinger Band on October 28, 2026
MDWD broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 36 similar instances where the stock broke above the upper band. In 32 of the 36 cases the stock fell afterwards. This puts the odds of success at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where MDWD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDWD as a result. In 72 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for MDWD turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
MDWD moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDWD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for MDWD entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MDWD's RSI Oscillator exited the oversold zone, 29 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The 10-day moving average for MDWD crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +10.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDWD advanced for three days, in 183 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.161) is normal, around the industry mean (3.498). P/E Ratio (-8.906) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.045) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. MDWD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDWD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement